Galapagos

Pioneering For Patients

We are Galapagos

We are a biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life.

Our Technology Platforms

Cell Therapy

  • Scalable, decentralized, fast: stem-like, early memory cells near patients in median 7 days vein-to-vein
  • High-yielding discovery engine: multi-targeting, next-generation cell therapies
  • Diversify and grow: through partnerships and M&A
Discover more

Our Technology Platforms

Small Molecules

We are seeking partners to take over our small molecules’ assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic lupus erythematosus, dermatomyositis, and other potential auto-immune indications.

Learn more

LATEST PRESS RELEASES

More

Pioneering for Patients, with Patients!

Patients and Carers

At Galapagos, we put patients’ care and well-being first and foremost.

Our goal is to improve patients’ quality of life through life-changing science and innovation.

Discover our commitment to pioneering for patients, with patients!

Discover our commitment